Crossing the blood-brain-barrier. Novel substances for the medication treatment of brain metastases;Überwindung der blut-hirn-schranke. Neue substanzen zur medikamentösen hirnmetastasentherapie

Onkologe

Volumn 14, Issue 3, 2008, Pages 260-266

  Kiewe, P ^a   Korfel, A ^a   Weller, M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Blood brain barrier; Brain metastases; Novel cytostatic agents; Targeted drugs; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYTOSTATIC AGENT; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOTHILONE B; GEFITINIB; LAPATINIB; METHOTREXATE; NAVELBINE; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CARCINOMA; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; HUMAN; LUNG CARCINOMA; MONOTHERAPY; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 40549095671     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-008-1316-2     Document Type: Review

References (30)

1. Patchell RA, Tibbs PA, Walsh JW et al. (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494-500
2. Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33: 583-590
3. Smith ML, Lee JY (2007) Stereotactic radiosurgery in the management of brain metastasis. Neurosurg Focus 22: E5
4. Khuntia D, Brown P, Li J, Mehta MP (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24: 1295-1304
5. Weller M (2003) Neuroonkologie. Nervenarzt 74: 1139-1149
6. Nussbaum ES, Djalilian HR, Cho KH, Hall WA (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78: 1781-1788
7. Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25: 2306-2312
8. Robinet G, Thomas P, Breton JL et al. (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 12: 59-67
9. Boogerd W, Dalesio O, Bais EM, Sande JJ van der (1992) Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69: 972-980
10. Franciosi V, Cocconi G, Michiara M et al. (1999) Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85: 1599-1605
11. Kaba SE, Kyritsis AP, Hess K et al. (1997) TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15: 1063-1070
12. Abrey LE, Olson JD, Raizer JJ et al. (2001) A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53: 259-265
13. Christodoulou C, Bafaloukos D, Kosmidis P et al. Hellenic Cooperative Oncology Group (2001) Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: 249-254
14. Dziadziuszko R, Ardizzoni A, Postmus PE et al. EORTC Lung Cancer Group (2003) Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 39: 1271-1276
15. Omuro AM, Raizer JJ, Demopoulos A et al. (2006) Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol 78: 277-280
16. Agarwala SS, Kirkwald JM, Gore M et al. (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 22: 2101-2107
17. Danson S, Lorigan P, Arance A et al. (2003) Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 21: 2551-2557
18. Trudeau ME, Crump M, Charpentier D et al. (2006) Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 17: 952-956
19. Wong ET, Berkenblit A (2004) The role of topotecan in the treatment of brain metastases. Oncologist 9: 68-79
20. Oberhoff C, Kieback DG, Wurstlein R et al. (2001) Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study. Onkologie 24: 256-260
21. Korfel A, Oehm C, Pawel J von et al. (2002) Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: a multicentre phase II study. Eur J Cancer 38: 1724-1729
22. Ko Y, Neuhaus T, Müller R et al. (2007) A phase III trial of topotecan and whole brain radiation (WBRT) therapy for patients with CNS metastases due to lung cancer. J Clin Oncol (ASCO Annual Meeting Proceedings Part I) 25: 2049 (Abstract)
23. Abrey L, Wen PY, Govindan R et al. (2007) Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study. J Clin Oncol (ASCO Annual Meeting Proceedings Part I) 25: 18058 (Abstract)
24. Ceresoli GL, Cappuzzo F, Gregorc V et al. (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15: 1042-1047
25. Shimato S, Mitsudomi T, Kosaka T et al. (2006) EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neurooncol 8: 137-144
26. Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743
27. Lin NU, Dieras V, Paul D et al. EGF105084 Study Group (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol (ASCO Annual Meeting Proceedings Part I) 25: 1012 (Abstract)
28. Massard C, Zonierek J, Laplanche A et al. (2006) Incidence of brain metastasis in advanced renal carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor. Ann Oncol (Abstact Book 31st ESMO Congress 2006) 17: Abstract 454P
29. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259
30. Lee TH, Avraham HK, Jiang S, Avraham S (2003) Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem 278: 5277-5284